For this period, Quest Diagnostics reports a gross margin of 33.1%, an operating margin of 14.6%, an EBITDA margin of 19.5%, and a net margin of 9.5%. Net margin recorded the largest improvement, gaining by 0.6 percentage points. Gross margin recorded the largest decline, dropping by 0.2 percentage points.
Quest Diagnostics's margins averaged 33% gross, 13.85% operating, 18.88% EBITDA, and 9.03% net during the last 3 years. Currently all four current margins are above their three-year averages.
The largest positive change was in net margin, up 0.6 percentage points. Operating margin also expanded by 0.5 percentage points and Ebitda margin also expanded by 0.2 percentage points, while gross margin contracted by 0.2 percentage points.
Quest Diagnostics recorded an average gross margin of 33% across the last 3 years. Quest Diagnostics currently reports a gross margin of 33.1%, 0.1 percentage points above its three-year average. Looking back over the last 3 years, Quest Diagnostics's gross margin reached 33.3% at its highest point in Sep 2025 and 32.7% at its lowest in Sep 2024.
Across the last 3 years, Quest Diagnostics's operating margin averaged 13.85%. The current operating margin stands at 14.6%, 0.8 percentage points above its three-year average. Operating margin was highest at 14.6% in Sep 2026 and lowest at 13.1% in Sep 2024.
Quest Diagnostics's EBITDA margin averaged 18.88% in the last 3 years. The current EBITDA margin stands at 19.5%, 0.6 percentage points above its three-year average. Over the last 3 years, Quest Diagnostics's EBITDA margin peaked at 19.5% in Sep 2026 and reached a low of 18.1% in Sep 2024.
Over the last 3 years, the average net margin for Quest Diagnostics was 9.03%. The latest net margin for Quest Diagnostics is 9.5%, 0.5 percentage points above its three-year average. Quest Diagnostics's net margin ranged from a low of 8.8% in Sep 2024 to a high of 9.5% in Sep 2026.
With a gross margin of 33.1%, DGX ranks lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.3%, Quest Diagnostics's gross margin is 52% lower.
The current gross margin for DGX is 33.1% as of Sep 30, 2026.
As of Sep 30, 2026, DGX has an operating margin of 14.6%.
The current EBITDA margin for DGX is 19.5% as of Sep 30, 2026.
As of Sep 30, 2026, DGX has a net margin of 9.5%.
The three-year average margins for DGX were 33.0% gross, 13.9% operating, 18.9% EBITDA, and 9.0% net.
Over this 5-year history, DGX peaked at 39% gross in Dec 2021, 22.1% operating in Dec 2021, 29.2% EBITDA in Dec 2021, and 18.5% net in Dec 2021.
Looking back across 5 years, DGX reached its lowest margins at 32.7% gross in Sep 2024, 12.2% operating in Sep 2023, 16.5% EBITDA in Mar 2023, and 8.2% net in Sep 2023.